CD38 and Miyoshi myopathy: Thrombotic events (TE), indeed, represent a significant and potentially life-threatening complication in patients with MM, particularly those undergoing treatment with IMiDs such as thalidomide (Thal), lenalidomide (Len), and pomalidomide (Pom) [2,3,4,5], essential agents for MM therapy with a remarkable efficacy when combined with anti-CD38 monoclonal antibodies [6,7,8].